FAKTOR OPTIONSSCHEIN - INCYTE CO. | Market Closed - BOERSE MUENCHEN 19:26:43 21/06/2024 BST | ||
| 9.41 EUR | +1.40% |
|
| Current month | +45.44% | ||
| 1 month | +48.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
INCYTE CORPORATION
Latest news about INCYTE CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 21/06/24 | 9.41 | +1.40% |
| 20/06/24 | 9.28 | +11.67% |
| 19/06/24 | 8.31 | -3.71% |
| 18/06/24 | 8.63 | -6.50% |
| 17/06/24 | 9.23 | +3.01% |
Real-time BOERSE MUENCHEN
Last update June 21, 2024 at 07:26 pm
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | INCYTE CORPORATION |
| Issuer | Goldman Sachs |
| WKN | GQ8CQM |
| ISIN | DE000GQ8CQM3 |
| Date issued | 01/11/2023 |
| Strike | 49.89 $ |
| Maturity | Unlimited |
| Parity | 1.28 : 1 |
| Emission price | 8.97 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 19.59 € |
|---|---|
| Lowest since issue | 3.77 € |
| Spread | 0.07 € |
| Spread % | 0.71% |
Company Profile
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
-
Consensus: Incyte Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
63.22
USD
Average target price
72.8
USD
Spread / Average Target
+15.15%
- Stock Market
- Certificates
- Certificat
